Creative Medical Technology Holdings Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem For Addressing Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as
